Table 3. HNSCC-associated changes in the serum levels of 5′ tRNA halves.
| tRNA1 | Genomic coordinates | CPM2 | FC3 | Pvalue3 | FDR3 |
|---|---|---|---|---|---|
| Cys-GCA | chr1:93981834-93981906 | 143.2 | 5.6 | 7.64E-08 | 7.96E-07 |
| Tyr-GTA | chr2:27273650-27273738 | 113.6 | 4.0 | 6.20E-06 | 4.46E-05 |
| Ala-TGC | chr6:28726141-28726212 | 189.6 | 3.5 | 1.31E-08 | 1.58E-07 |
| Lys-CTT | chr16:3225692-3225764 | 1540.0 | −3.4 | 4.95E-11 | 8.13E-10 |
| Arg-CCG | chr17:66016013-66016085 | 138.3 | −3.9 | 7.20E-06 | 5.00E-05 |
| chr6:28849165-28849237 | 129.4 | −3.9 | 5.07E-09 | 6.33E-08 | |
| chr15:79152904-79152976 | 8332.2 | −4.0 | 5.43E-16 | 2.00E-14 | |
| Glu-TTC | chr13:45492062-45492133 | 2948.1 | −4.1 | 8.19E-16 | 2.84E-14 |
| chr14:58706613-58706685 | 3533.9 | −4.3 | 3.52E-14 | 1.10E-12 | |
| chr16:3241501-3241573 | 7938.2 | −4.5 | 3.12E-16 | 1.22E-14 | |
| chr16:3207406-3207478 | 374.3 | −4.6 | 2.34E-08 | 2.71 E-07 | |
| Val-TAC | chr6:27258405-27258477 | 582.8 | −4.6 | 3.99E-07 | 3.72E-06 |
| chr2:131094701-131094772 | 612.6 | −4.6 | 8.66E-17 | 3.61E-15 | |
| Val-CAC | chr5:180649395-180649467 | 10608.0 | −5.0 | 7.75E-10 | 1.03E-08 |
| Glu-CTC | chr6:28949976-28950047 | 14851.5 | −5.0 | 6.09E-24 | 9.52E-22 |
| chr1:161431809-161431880 | 3246.5 | −5.0 | 1.63E-24 | 4.07E-22 | |
| chr13:41634874-41634945 | 591.9 | −5.0 | 2.14E-15 | 7.05E-14 | |
| chr1:161424398-161424469 | 3189.5 | −5.0 | 8.06E-20 | 4.20E-18 | |
| chr1:161439189-161439260 | 3227.3 | −5.1 | 1.85E-23 | 2.27E-21 | |
| chr19:4724647-4724719 | 1610.7 | −5.1 | 1.29E-11 | 2.59E-10 | |
| chr1:249168447-249168518 | 14777.2 | −5.2 | 1.95E-24 | 4.07E-22 | |
| chr5:180600650-180600722 | 39309.5 | −5.3 | 4.09E-10 | 5.80E-09 | |
| chr6:126101393-126101464 | 3240.3 | −5.3 | 3.56E-23 | 3.18E-21 | |
| chr6:26538282-26538354 | 38899.7 | −5.4 | 1.56E-10 | 2.27E-09 | |
| chr1:145399233-145399304 | 3225.7 | −5.4 | 1.45E-24 | 4.07E-22 | |
| chr1:161417018-161417089 | 3243.8 | −5.4 | 2.18E-23 | 2.27E-21 | |
| chr5:180524070-180524142 | 38336.8 | −5.8 | 1.35E-10 | 2.00E-09 | |
| chr5:180529253-180529325 | 10581.3 | −5.9 | 8.73E-11 | 1.40E-09 | |
| chr1:149298555-149298627 | 10125.3 | −6.0 | 2.66E-11 | 4.90E-10 | |
| chr1:149684088-149684161 | 10446.6 | −6.1 | 3.98E-11 | 6.91E-10 | |
| chr15:26327381-26327452 | 2569.5 | −6.2 | 6.61E-22 | 5.16E-20 | |
| chr1:161369490-161369562 | 10640.4 | −6.3 | 4.74E-11 | 8.01E-10 | |
| Val-AAC | chr3:169490018-169490090 | 36234.5 | −6.5 | 1.51E-11 | 2.96E-10 |
| Trp-CCA | chr17:8089676-8089747 | 145.1 | −6.6 | 4.53E-08 | 4.96E-07 |
| chr5:180596610-180596682 | 37347.2 | −6.6 | 1.11E-11 | 2.31E-10 | |
| chr5:180645270-180645342 | 9935.0 | −6.6 | 1.79E-12 | 4.47E-11 | |
| chr6:27648885-27648957 | 10105.2 | −6.6 | 1.05E-11 | 2.26E-10 | |
| chr5:180591154-180591226 | 37053.9 | −6.7 | 5.06E-12 | 1.17E-10 | |
| Gly-CCC | chr1:17053780-17053850 | 151.8 | −6.7 | 3.84E-11 | 6.85E-10 |
| chr6:27721179-27721251 | 10156.5 | −6.8 | 4.99E-12 | 1.17E-10 | |
| chr6:27618707-27618779 | 9941.2 | −6.9 | 6.51E-12 | 1.45E-10 | |
| chr11:59318102-59318174 | 484.7 | −8.2 | 2.03E-13 | 5.76E-12 | |
| Arg-TCT | chr1:94313129-94313213 | 3283.4 | −10.0 | 3.88E-18 | 1.73E-16 |
| chrX:18693029-18693101 | 459.1 | −10.4 | 3.06E-19 | 1.47E-17 | |
| chr6:27248049-27248121 | 18754.0 | −11.2 | 1.46E-12 | 3.81E-11 | |
| chr17:19411494-19411565 | 172.1 | −12.6 | 9.25E-13 | 2.51E-11 | |
| chr6:27173867-27173939 | 215.8 | −14.0 | 3.75E-14 | 1.12E-12 | |
| chr1:149294666-149294736 | 1407.1 | −23.4 | 2.35E-21 | 1.63E-19 | |
| chr6:27203288-27203360 | 655.2 | −24.4 | 5.65E-21 | 3.53E-19 |
1
tRNA isoacceptor identity with corresponding genomic positions in the human hg19 genome. All small RNAs are derived from the 5′ end of tRNAs.
2
Average tRNA read counts-per-million computed over all libraries and taking into account the estimated dispersions and the libraries sizes. It represents a measure of the overall expression level of the tRNA fragments.
3
Fold change, P value and FDR for differential abundance were computed by EdgeR from pairwise comparisons for each tRNA fragment between the control and cancer groups.